Minimum veniam quis
Lorem ipsum dolor sit amet
Young & Partners is an international investment banking firm uniquely dedicated to the chemical and life science industries. The Firm is a licensed broker-dealer and a member of the FINRA and SIPC. It is a highly regarded chemical industry and life sciences investment banking firm that is in its 24th year.
The Firm provides extensive services to large and middle market clients in the areas of:
Lorem ipsum valor
The Firm’s activities and projects are highly international in nature.
The senior members of the Firm have completed a large number of transactions and financings for companies on a global basis over many years.
Compared to other investment banks, Young & Partners offers clients advantages in the following categories:
Lorem Ipsum
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem Ipsum
One of only a few independent investment banks focused solely on the chemical and life science industries
Lorem Ipsum
Well recognized and highly regarded in the industry
Lorem Ipsum
Emphasizes long-term relationships with clients
Lorem Ipsum
Extensive and focused knowledge of chemical and life science industry M&A and financing dynamics
Lorem Ipsum
Structured to provide consistent senior attention and involvement for all projects
Lorem Ipsum
Extensive and centralized senior contacts throughout the industry
Lorem Ipsum
Flexibility to assist clients in all types of transactions, regardless of size or type
Lorem Ipsum
The only firm that combines first rate investment banking, deep industry knowledge, and corporate strategy consulting expertise in one firm
Lorem Ipsum
The Firm has sponsored the leading Senior Chemical Executive Conference every fall for many years on “Strategic, Financial and Shareholder Issues for Chemical Executives”.
The Firm has been hosting an annual “Pharmaceutical Executive Summit” for many years that gathers together senior executives and features speakers on important biotech and pharma topics.
In addition, the Firm selectively engages in principal investing.